Evidence map›Paper›PMID 42036102›Full record

ArticleJornal de pediatria

Assessment of abdominal symptoms and intestinal inflammation in children and adolescents with cystic fibrosis without highly effective modulator therapy.

Gabriel Cezar Dos Santos, Lorenna Cristina Montera, Lívia Moreira Genaro, Beatriz Alves Guerra Rodrigues, Raquel Franco Leal, Antonio Fernando Ribeiro, Jose Dirceu Ribeiro, Elizete Aparecida Lomazi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Jornal de pediatria. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gabriel Cezar Dos SantosUniversidade Estadual de Campinas (UNICAMP), Faculdade de Ciências Médicas (FCM), Graduate Program in Child and Adolescent Health, Campinas, SP, Brazil. Electronic address: gabrielcezar.unicamp@gmail.com.
Lorenna Cristina MonteraUniversidade Estadual de Campinas (UNICAMP), Faculdade de Ciências Médicas (FCM), Graduate Program in Child and Adolescent Health, Campinas, SP, Brazil.
Lívia Moreira GenaroUniversidade Estadual de Campinas (UNICAMP), Faculdade de Ciências Médicas (FCM), Surgery Department, Gastrocenter, Colorectal Surgery Unit, Inflammatory Bowel Disease Research Laboratory (LABDII), Campinas, SP, Brazil.
Beatriz Alves Guerra RodriguesUniversidade Estadual de Campinas (UNICAMP), Faculdade de Ciências Médicas (FCM), Surgery Department, Gastrocenter, Colorectal Surgery Unit, Inflammatory Bowel Disease Research Laboratory (LABDII), Campinas, SP, Brazil.
Raquel Franco LealUniversidade Estadual de Campinas (UNICAMP), Faculdade de Ciências Médicas (FCM), Surgery Department, Gastrocenter, Colorectal Surgery Unit, Inflammatory Bowel Disease Research Laboratory (LABDII), Campinas, SP, Brazil.
Antonio Fernando RibeiroUniversidade Estadual de Campinas (UNICAMP), Faculdade de Ciências Médicas (FCM), Department of Pediatrics, Campinas, SP, Brazil.
Jose Dirceu RibeiroUniversidade Estadual de Campinas (UNICAMP), Faculdade de Ciências Médicas (FCM), Department of Pediatrics, Campinas, SP, Brazil.
Elizete Aparecida LomaziUniversidade Estadual de Campinas (UNICAMP), Faculdade de Ciências Médicas (FCM), Department of Pediatrics, Campinas, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCystic fibrosis (CF) is a rare genetic disease caused by mutations in the CFTR gene, resulting in a dysfunctional protein that affects various systems in the body, including the gastrointestinal (GI) tract. The changes caused by CF in the GI tract include dysmotility, dysbiosis, intestinal inflammation, and abdominal symptoms such as pain, altered bowel habits, and distension, which are frequent in people with CF. This study aims to establish the prevalence of these complaints in children with CF and investigate associations between symptoms, clinical conditions, and markers of intestinal inflammation.

methodsTwenty-two pediatric patients with a genetic diagnosis of CF, followed at a Brazilian reference center, were included. Methods involved a systematic assessment of gastrointestinal symptoms using a questionnaire, biochemical analysis of fecal calprotectin (FC) as a marker of intestinal inflammation, and collection of clinical, anthropometric, laboratory, and imaging data from medical records.

results86.3% (n = 19) of participants showed elevated FC levels (> 50 gt; 50 mcg/g), indicating a high prevalence of intestinal inflammation. The most common abdominal symptoms were pain and flatulence, present in about half of the patients. No significant associations were observed between FC levels and clinical or symptomatic variables.

conclusionThere is a high prevalence of intestinal inflammation and abdominal symptoms in this sample of Brazilian children with CF, highlighting the importance of systematically investigating these symptoms.

Indexed as

Abdominal PainCystic FibrosisInflammationAdolescentBiomarkersBrazilChildChild, PreschoolFecesFemaleHumansLeukocyte L1 Antigen ComplexMalePrevalenceBiomarkersLeukocyte L1 Antigen ComplexAbdominal painCystic fibrosisFecal calprotectinInflammationIntestinal

Identifiers

PMID42036102
PMCPMC13188096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.